Medivation Plans “Aggressive” Timeline For Alzheimer’s, Huntington’s NDAs
This article was originally published in The Pink Sheet Daily
Executive Summary
Dimebon safety profile compares favorably to Aricept, Exelon and Razadyne, CEO says.
You may also be interested in...
Alzheimer’s Drug Development Comparable To Cancer 50 Years Ago, Says Targacept CEO
Biomarkers and diagnostic tools must be developed to allow drug manufacturers to target Alzheimer’s disease modification, BioInvestor Forum panelists say.
Prestwick's Xenazine Faces Advisory Committee Review
Huntington's disease treatment tetrabenazine received an FDA "approvable" letter March 24.
Novartis Institute For Tropical Diseases Could Have TB Drug In Clinic By Late 2007
Singapore-based institute is also looking at dengue fever and malaria, exec says in interview with “The Pink Sheet” DAILY.